SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001021771-24-000103 from BioRestorative Therapies, Inc. (BRTX) (CIK 0001505497) (BRTX)

BioRestorative Therapies, Inc. (BRTX) (CIK 0001505497)
Date: April 17, 2024 · CIK: 0001505497 · Accession: 0001021771-24-000103

AI Filing Summary & Sentiment

File numbers found in text: 333-278488

Date
April 17, 2024
Author
/s/ Lance Alstodt
Form
CORRESP
Company
BioRestorative Therapies, Inc. (BRTX) (CIK 0001505497)

Letter

BioRestorative Therapies, Inc.

40 Marcus Drive, Suite One

Melville, New York 11747

April 17, 2024

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, NE

Washington, DC 20549

Re: BioRestorative Therapies, Inc.

Registration Statement on Form S-1

Filed April 3, 2024

File No. 333-278488

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, BioRestorative Therapies, Inc. (the “Registrant”) hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 5:00 p.m. ET on April 18, 2024, or as soon thereafter as practicable. The Registrant hereby authorizes Fred Skolnik, an attorney with the Registrant’s outside legal counsel, Certilman Balin Adler & Hyman, LLP, to orally modify or withdraw this request for acceleration.

The Registrant hereby acknowledges that:

should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

the Registrant may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

The Registrant respectfully requests that it be notified of such effectiveness by a telephone call to Mr. Skolnik at (516) 476-7486. Please also provide a copy of the Commission’s order declaring the Registration Statement on Form S-1 effective to Mr. Skolnik via email at fskolnik@certilmanbalin.com and via mail at Certilman Balin Adler & Hyman, LLP, 90 Merrick Avenue, 9th Floor, East Meadow, NY 11554.

Very truly yours,
/s/ Lance Alstodt

Show Raw Text
CORRESP
1
filename1.htm

  BioRestorative Therapies, Inc.

  40 Marcus Drive, Suite One

  Melville, New York 11747

  April 17, 2024

  VIA EDGAR

  U.S. Securities and Exchange Commission

  Division of Corporation Finance

  100 F Street, NE

  Washington, DC 20549

  Re:        BioRestorative Therapies, Inc.

  Registration Statement on Form S-1

  Filed April 3, 2024

  File No. 333-278488

  Ladies and Gentlemen:

  Pursuant to Rule 461 under the Securities Act of 1933, as amended, BioRestorative Therapies, Inc. (the “Registrant”) hereby requests acceleration of effectiveness of the above referenced Registration
    Statement so that it will become effective at 5:00 p.m. ET on April 18, 2024, or as soon thereafter as practicable.  The Registrant hereby authorizes Fred Skolnik, an attorney with the Registrant’s outside legal counsel, Certilman Balin Adler &
    Hyman, LLP, to orally modify or withdraw this request for acceleration.

  The Registrant hereby acknowledges that:

        •

          should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

        •

          the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing;
            and

        •

          the Registrant may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

  The Registrant respectfully requests that it be notified of such effectiveness by a telephone call to Mr. Skolnik at (516) 476-7486.  Please also provide a copy of the Commission’s order declaring the
    Registration Statement on Form S-1 effective to Mr. Skolnik via email at fskolnik@certilmanbalin.com and via mail at Certilman Balin Adler & Hyman, LLP, 90 Merrick Avenue, 9th Floor, East Meadow, NY 11554.

  Very truly yours,

  /s/ Lance Alstodt

  Lance Alstodt

  President and Chief Executive Officer

  cc: Certilman Balin Adler & Hyman, LLP